Stevens Capital Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Stevens Capital Management’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-7,152	Closed	-$151K	–	1341
2015 Q3	$151K	Buy	7,152 +4,312	+152%	+$148K	0.01%	866
2015 Q2	$141K	Sell	2,840 -1,265	-31%	-$75.6K	0.01%	923
2015 Q1	$321K	Buy	4,105 +822	+25%	+$51K	0.01%	726
2014 Q4	$199K	Sell	3,283 -1,040	-24%	-$52.2K	0.01%	865
2014 Q3	$184K	Buy	4,323 +2,147	+99%	+$115K	0.01%	874
2014 Q2	$134K	Sell	2,176 -1,288	-37%	-$74.9K	﹤0.01%	982
2014 Q1	$225K	Buy	3,464 +1,034	+43%	+$69.9K	0.01%	893
2013 Q4	$137K	Sell	2,430 -8,095	-77%	-$455K	﹤0.01%	951
2013 Q3	$645K	Buy	10,525 +5,490	+109%	+$372K	0.02%	582
2013 Q2	$294K	Buy	+5,035	New	+$310K	0.01%	717

Other funds holding OREX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stevens Capital Management's OREX Position: Q4 2015 in Review

Stevens Capital Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2015, closing a stake of 7,152 shares — an estimated $151K sold.

Stevens Capital Management first reported a position in OREX in Q2 2013 and held it in 10 quarters. The position peaked at $645K in Q3 2013. 121 funds tracked by Wall St. Rank hold OREX as of Q4 2015.

Stevens Capital Management reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
Stevens Capital Management sold 7,152 Orexigen Therapeutics, Inc. shares in Q4 2015, an estimated $151K.
Stevens Capital Management first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 10 quarters.
Stevens Capital Management's Orexigen Therapeutics, Inc. position peaked at $645K in Q3 2013.
121 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2015.

Based on Stevens Capital Management's 13F filing for Q4 2015, filed 5 Feb 2016.